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Glioblastoma multiforme (GBM) is a highly aggressive, treatment resistant, and almost invariably 
fatal brain cancer involving neuro-protective glial cells. Recently, brain tumor-initiating cells (BTIC) 
have been identified and are believed to be the stem cells that drive GBM. Cancer therapies that 
target BTIC are likely to increase patient survival to this otherwise devastating disease. However, the 
proteins that are involved in GBM tumor maintenance mostly remain enigmatic. 
Kinases influence nearly every cellular process. Therefore, the Paddison Lab (Human Biology 
Division) and the Olson Lab (Clinical Research Division) recently pioneered a screen to uncover key 
kinases functioning in BTIC to promote GBM tumor survival. The results of this work were recently 
published in a paper appearing in the journal Cancer Discovery, the lead author of which was 
postdoctoral associate Dr. Yu Ding of the Paddison Lab. The authors’ screen was based on the 
depletion of 713 human kinases (by shRNA) and the analysis of defectivein vitro BTIC expansion. 
Ding et al. identified about 48 candidate kinases that influence BTIC proliferation. By analyzing gene 
expression and other parameters directly from GBM tumor samples, the researchers narrowed the 
list to 37 proteins in the GBM network. Intriguingly, the largest GBM subnetwork contained four 
mitotic kinases with BubR1 scoring as the top ranked screen hit that was required for BTIC 
proliferation. In order for BubR1 to be a good pharmacological candidate, it should play an essential 
function in BTIC but not control non-tumorigenic neural stem cells (NSC). Indeed, BubR1 inhibition 
significantly halted BTIC growth but did not affect the proliferation of NSC. BubR1 therefore 
appeared to be a prime protein for BTIC-specific survival. This result suggested that some defect in 
mitosis underlies GBM, and it motivated the authors to answer the specific question: What aspect of 
BubR1 function is required in BTIC? 
Mitosis is the cell cycle stage devoted to chromosome segregation, in which BubR1 plays multiple 
roles. Prior to mitosis, each chromosome is duplicated and is physically paired to its “twin”; these 
attached chromosomes are called sister chromatids. Each “twin” builds a kinetochore, resulting in 
the formation of two sister kinetochores on each paired sister chromatid. The kinetochore (KT) is a 
megadalton-sized protein complex that binds to mitotic spindle microtubules (MT) and to 
chromosomes to mediate chromosome segregation. BubR1 localizes to kinetochores, leading the  
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authors to posit that the necessity for BubR1 in BTIC was due to impaired KT-MT dynamics in those 
cells. Indeed, Ding et al. found that BTIC, but not NSC, depleted of BubR1 exhibited chromosome 
congression and segregation defects, and decreased separation of sister kinetochores (termed IKD 
for inter-kinetochore distance). Interestingly, the authors found that the IKD were significantly shorter 
in the shBubR1-sensitive BTIC compared to control cells or even to two BTIC isolates that were 
insensitive to shBubR1. These data indicate that BTIC have altered kinetochore activity that requires 
BubR1 function for cell survival.  
The authors also asked whether the change in IKD was specific to BTICs or if other transformed 
cells exhibited a similar phenotype. They were surprised to find that IKD of Ras-transformed 
(oncogenic) mouse embryonic fibroblasts (MEF) were shorter than untransformed control MEF, with 
the transformed MEF being sensitive to BubR1 levels and exhibiting reduced proliferation upon 
BubR1 knockdown. 
BubR1 is a multi-domain protein, and the authors wanted to determine which region of BubR1 was 
required for BTIC and Ras-transformed MEF viability. By assessing the ability of BubR1 deletion 
mutants to rescue the proliferation defects of BubR1-depleted cells, the kinetochore-targeting GLEB 
but not kinase domain of BubR1 was shown to be essential for BTIC and oncogenic MEF survival. 
This indicated a critical role for BubR1 at the kinetochore in transformed cells. Lastly, the 
researchers injected mice with either control or BubR1-depleted BTIC, after which they assessed the 
ability of the BTIC to form tumors. 90% of mice that were injected with control BTIC had succumbed 
to tumors by day 250 post-injection, while none of the mice injected with BubR1-depleted BTIC had 
died. 
Altogether, these data indicate that BubR1 acts in a kinase-independent way at the kinetochore of 
BTIC and other transformed cells to facilitate a kinetochore function that is distinctly required upon 
oncogenic transformation. Future investigations will uncover the key kinetochore proteins to which 
BubR1 binds to promote chromosome segregation and viability in tumors. It is also exciting to 
speculate that BubR1 inhibition may have an anti-tumorigenic effect in human cancer, particularly 
those that exhibit decreased IKD. 
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Modified from the manuscript 
Wild-type mouse embryonic fibroblast (MEF, left) and Ras-
transformed oncogenic MEF (right) stained with kinetochore 
antibodies (green and red). The inset shows a pair of sister 
kinetochores (a single kinetochore is depicted by one green 
and red focus). The distance between sister kinetochores is 
significantly shorter in Ras-transformed MEF indicating 
kinetochore dysfunction upon oncogenic transformation. 
 
